MX2010001071A - Formas de dosificacion retentivas gastricas pulsatiles. - Google Patents

Formas de dosificacion retentivas gastricas pulsatiles.

Info

Publication number
MX2010001071A
MX2010001071A MX2010001071A MX2010001071A MX2010001071A MX 2010001071 A MX2010001071 A MX 2010001071A MX 2010001071 A MX2010001071 A MX 2010001071A MX 2010001071 A MX2010001071 A MX 2010001071A MX 2010001071 A MX2010001071 A MX 2010001071A
Authority
MX
Mexico
Prior art keywords
dosage forms
gastric retentive
stomach
administration
acid
Prior art date
Application number
MX2010001071A
Other languages
English (en)
Inventor
Bret Berner
Sui Yuen Eddie Hou
Verne Earle Cowles
Chien-Hsuan Han
Ryan Douglas Fell
Chung-Hong Gu
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depomed Inc filed Critical Depomed Inc
Publication of MX2010001071A publication Critical patent/MX2010001071A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen formas de dosificación para liberación retardada y pulsada de agentes terapéuticos en el estómago. Las formas de dosificación son formas de dosificación retentivas gástricas que logran la liberación del agente terapéutico en el estómago y tracto gastrointestinal superior subsiguiente a la administración de la forma de dosificación. Las formas de dosificación encuentran uso particular en la administración de agentes activos lábiles a ácido tales como inhibidores de bomba de protones, y en el tratamiento de secreción de ácido gástrico tal como enfermedad de reflujo gastroesofágico (GERD) e irrupción ácida nocturna (NAB).
MX2010001071A 2007-07-27 2008-07-25 Formas de dosificacion retentivas gastricas pulsatiles. MX2010001071A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95250107P 2007-07-27 2007-07-27
US96771707P 2007-09-05 2007-09-05
PCT/US2008/009139 WO2009017716A2 (en) 2007-07-27 2008-07-25 Pulsatile gastric retentive dosage forms

Publications (1)

Publication Number Publication Date
MX2010001071A true MX2010001071A (es) 2010-03-09

Family

ID=40219415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001071A MX2010001071A (es) 2007-07-27 2008-07-25 Formas de dosificacion retentivas gastricas pulsatiles.

Country Status (8)

Country Link
US (2) US20090028941A1 (es)
EP (1) EP2192892A2 (es)
JP (1) JP2010534721A (es)
CN (1) CN101888828A (es)
AU (1) AU2008282900B2 (es)
CA (1) CA2694602A1 (es)
MX (1) MX2010001071A (es)
WO (1) WO2009017716A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20070253A1 (it) * 2007-11-09 2009-05-10 Valpharma Internat S P A Formulazioni farmaceutiche per la somministrazione di ipp.
US8377453B2 (en) 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009256423A1 (en) * 2008-06-03 2009-12-10 Novartis Ag Pulsatile release of valsartan
WO2010018593A2 (en) * 2008-07-03 2010-02-18 Torrent Pharmaceuticals Ltd. Gastric acid resistant benzimidazole multiple unit tablet composition
US9161911B2 (en) 2008-08-15 2015-10-20 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
US20120141584A1 (en) * 2009-08-26 2012-06-07 Aptapharma, Inc. Multilayer Minitablets
BR112012004525A2 (pt) * 2009-08-31 2016-03-22 Depomed Inc composição farmacêuticas gástrico-rententivas para liberação imediata ou prolongada de acetaminofeno
US20110104272A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
WO2011146611A1 (en) * 2010-05-18 2011-11-24 Abon Pharmaceuticals, Llc Modified gastroretentive drug delivery system for amine drugs
WO2012022498A1 (en) 2010-08-18 2012-02-23 Evonik Röhm Gmbh Gastric resistant pharmaceutical or nutraceutical formulation comprising one or more salts of alginic acid
CA2850468C (en) 2010-09-28 2019-08-13 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
UA112855C2 (uk) * 2010-12-29 2016-11-10 Др. Редді'С Лабораторіс Лтд. Композиції бензімідазолів з модифікованим вивільненням
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
US8722083B2 (en) 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
CN105163743A (zh) * 2013-02-13 2015-12-16 红山生物医药有限公司 用于治疗幽门螺杆菌的药物组合物
CN107530289A (zh) * 2015-02-27 2018-01-02 扣带回治疗学有限公司 三脉冲释放***制剂
EP3277267B1 (en) * 2015-03-31 2021-01-06 Laboratorios Bagó S.A. Enteric-coated pellets containing a proton pump inhibitor
CN108721242B (zh) * 2015-06-03 2021-03-02 南京三迭纪医药科技有限公司 药品剂型及其使用
JP6657974B2 (ja) * 2016-01-12 2020-03-04 トヨタ紡織株式会社 金属樹脂一体成形品及びその製造方法
KR101884230B1 (ko) * 2016-02-29 2018-08-01 주식회사 유영제약 에소메프라졸을 포함하는 제제
US10327994B2 (en) * 2016-05-02 2019-06-25 Dose Pack Llc System and methods for customized medicine dosages in a capsule
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
IL266377B2 (en) * 2016-12-02 2023-10-01 Clexio Biosciences Ltd Stomach retention system
CN108956912A (zh) * 2017-05-17 2018-12-07 亚宝药业集团股份有限公司 一种硝苯地平缓释片溶出曲线的测定方法
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10918597B2 (en) 2017-06-16 2021-02-16 Kashiv Specialty Pharmaceuticals, Llc Gastroretentive dosage forms for sustained drug delivery
US20210145777A1 (en) * 2017-06-16 2021-05-20 Altibio, Inc. Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
ES2861153T3 (es) 2018-06-18 2021-10-05 Composiciones de liberación prolongada que comprenden piridostigmina
US20230041197A1 (en) * 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3836866A4 (en) * 2018-08-15 2022-06-15 Lyndra Therapeutics, Inc. SYSTEMS FOR THE ENTERIC DELIVERY OF THERAPEUTIC AGENTS
CN111141854A (zh) * 2018-11-06 2020-05-12 中国科学院大连化学物理研究所 一种同时提取生物样品中极性和弱极性代谢物的方法
CN110372869B (zh) * 2019-08-24 2021-08-27 思必康（厦门）新材料有限公司 一种聚乙烯醇-肝素聚合物及其制备方法和应用
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US4487327A (en) * 1982-12-21 1984-12-11 Grayson Robert E Locking capsule
WO1988001160A1 (en) * 1986-08-19 1988-02-25 Hughes Raymond J Tamper evident capsule and insert device
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
US5443459A (en) * 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6120803A (en) * 1997-08-11 2000-09-19 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
EP1041968B1 (en) * 1997-12-29 2004-03-03 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6098629A (en) * 1999-04-07 2000-08-08 Endonetics, Inc. Submucosal esophageal bulking device
WO2001056544A2 (en) * 2000-02-04 2001-08-09 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
CA2412490A1 (en) * 2000-06-23 2002-01-03 Moshe Fleshner-Barak Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
MXPA03006217A (es) * 2001-01-12 2004-10-15 Sun Pharmaceutical Ind Ltd Sistema de administracion espaciada de farmacos.
EP1401423A4 (en) * 2001-05-29 2006-08-16 Depomed Dev Ltd METHOD FOR THE TREATMENT OF GASTROÖSOPHAGEAL REFLUX DISEASE AND NURSING ACID BREAKDOWN
BR0211317A (pt) * 2001-07-04 2004-12-14 Sun Pharmaceutical Ind Ltd Sistema para a liberação controlada de uma droga por meio de retenção gástrica
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
ITMI20012481A1 (it) * 2001-11-23 2003-05-23 Univ Parma Sistemi modulari per il rilascio controllato di sostanza a controllo spaziale e temporale
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
US20060135406A1 (en) * 2002-10-14 2006-06-22 Sabina Glozman Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
AU2004268446A1 (en) * 2003-08-27 2005-03-10 Vecta Ltd. Compositions for treating pathologies that necessitate suppression of gastric acid secretion
US20050249806A1 (en) * 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
ZA200805706B (en) * 2005-12-28 2010-02-24 Takeda Pharmaceutical Controlled release solid preparation
CA2635594A1 (en) * 2005-12-30 2007-07-12 Advancis Pharmaceutical Corporation Gastric release pulse system for drug delivery
EP3510988B1 (en) * 2006-01-18 2021-07-14 Intec Pharma Ltd. Delivery device for oral intake of an agent

Also Published As

Publication number Publication date
EP2192892A2 (en) 2010-06-09
CN101888828A (zh) 2010-11-17
US20160038411A1 (en) 2016-02-11
WO2009017716A3 (en) 2009-07-30
JP2010534721A (ja) 2010-11-11
CA2694602A1 (en) 2009-02-05
AU2008282900A1 (en) 2009-02-05
AU2008282900B2 (en) 2014-05-22
US20090028941A1 (en) 2009-01-29
WO2009017716A2 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
MX2010001071A (es) Formas de dosificacion retentivas gastricas pulsatiles.
EP2364144A4 (en) PHARMACEUTICAL FORM FOR ADMINISTRATION THROUGH THE MOUTH
CY1116050T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει εναν αναστολεα αντλιας πρωτονιου και ενα πρεβιοτικο για τη θεραπευτικη αντιμετωπιση ελκωδων βλαβων του στομαχου και του δωδεκαδακτυλου
TW200509923A (en) A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
HRP20151437T1 (hr) Brzo djelujuä†i inhibitor sekrecije želuäśane kiseline
WO2012117257A8 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
NO20092464L (no) Faste former av rasemisk ilaprazol
RU2010119041A (ru) Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи
NZ597534A (en) Method for treating a patient in need of aspirin therapy
HRP20211046T1 (hr) Upotreba derivata benzimidazola kod noćnog proboja kiseline
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
EA201591338A1 (ru) Гастроретентивная лекарственная форма секвестранта желчных кислот с замедленным высвобождением для перорального применения
NO20075393L (no) Akarbosebaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse
CN102397277A (zh) 包含埃索美拉唑的药物组合物
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
DK2125021T3 (da) Kombinationsterapi af sygdomme i de nedre urinveje med alfa2delta-ligander og NSAID'er
AU2016277587B2 (en) Buffered upper GI absorption promoter
WO2010117756A3 (en) Substituted benzimidazole pharmaceutical formulations
RU2015106931A (ru) Лекарственное средство от гастроэзофагеальной рефлюксной болезни
RU2007149399A (ru) Способ лечения больных колоректальным раком с метастазами в печень
JP2010529125A5 (es)
RU2016103912A (ru) Новый способ применения железа и новые композиции, приспособленные для указанной цели
RU2006132127A (ru) Применение нифуроксазида в качестве компонента комбинированной лекарственной терапии заболеваний, ассоциированных с helicobacter pylori, и способ лечения, направленный на эрадикацию возбудителя

Legal Events

Date Code Title Description
FA Abandonment or withdrawal